Ludo Van Den Bosch

List of Publications by Year
in descending order

189 papers	21,804 citations	19657 61 h-index	10158 140 g-index
195 all docs	195 docs citations	195 times ranked	29958 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Protein Phase Separation: A New Phase in Cell Biology. Trends in Cell Biology, 2018, 28, 420-435.	7.9	1,439
3	Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature Genetics, 2001, 28, 131-138.	21.4	967
4	Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nature Genetics, 2004, 36, 602-606.	21.4	541
5	Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nature Neuroscience, 2015, 18, 1226-1229.	14.8	528
6	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
7	Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Human Molecular Genetics, 2009, 18, 472-481.	2.9	512
8	Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature Neuroscience, 2005, 8, 85-92.	14.8	464
9	Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Molecular Cell, 2017, 65, 1044-1055.e5.	9.7	437
10	HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1â€“induced Charcot-Marie-Tooth disease. Nature Medicine, 2011, 17, 968-974.	30.7	405
11	Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nature Genetics, 2004, 36, 597-601.	21.4	395
12	Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. Journal of Cell Biology, 2008, 181, 37-41.	5.2	376
13	Spontaneous driving forces give rise to proteinâ^'RNA condensates with coexisting phases and complex material properties. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7889-7898.	7.1	365
14	Glial cells potentiate kainate-induced neuronal death in a motoneuron-enriched spinal coculture system. Brain Research, 1998, 807, 1-10.	2.2	342
15	Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nature Genetics, 2006, 38, 197-202.	21.4	323
16	Minocycline delays disease onset and mortality in a transgenic model of ALS. NeuroReport, 2002, 13, 1067-1070.	1.2	284
17	HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nature Communications, 2017, 8, 861.	12.8	275
18	EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nature Medicine, 2012, 18, 1418-1422.	30.7	269

#	Article	IF	Citations
19	Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium, 2010, 47, 165-174.	2.4	259
20	Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Scientific Reports, 2016, 6, 20877.	3.3	239
21	Ca2+-permeable AMPA receptors and selective vulnerability of motor neurons. Journal of the Neurological Sciences, 2000, 180, 29-34.	0.6	209
22	Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2008, 40, 29-31.	21.4	205
23	Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain, 2013, 136, 471-482.	7.6	205
24	ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurology, The, 2007, 6, 869-877.	10.2	195
25	Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14825-14830.	7.1	193
26	Energy metabolism in ALS: an underappreciated opportunity?. Acta Neuropathologica, 2018, 135, 489-509.	7.7	191
27	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95.	1.9	174
28	Modelling amyotrophic lateral sclerosis: progress and possibilities. DMM Disease Models and Mechanisms, 2017, 10, 537-549.	2.4	156
29	Spatiotemporal Proteomic Analysis of Stress Granule Disassembly Using APEX Reveals Regulation by SUMOylation and Links to ALS Pathogenesis. Molecular Cell, 2020, 80, 876-891.e6.	9.7	154
30	Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in Amyotrophic Lateral Sclerosis. Nature Communications, 2018, 9, 3683.	12.8	141
31	RNA toxicity in nonâ€coding repeat expansion disorders. EMBO Journal, 2020, 39, e101112.	7.8	135
32	Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Human Molecular Genetics, 2007, 16, 2359-2365.	2.9	134
33	Ablation of Proliferating Microglia Does Not Affect Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis Caused by Mutant Superoxide Dismutase. Journal of Neuroscience, 2008, 28, 10234-10244.	3.6	130
34	Progranulin is Neurotrophic In Vivo and Protects against a Mutant TDP-43 Induced Axonopathy. PLoS ONE, 2010, 5, e13368.	2.5	127
35	Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Human Molecular Genetics, 2013, 22, 1783-1790.	2.9	122
36	Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration. Journal of Neuroscience, 2008, 28, 10451-10459.	3.6	119

#	Article	IF	Citations
37	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
38	The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neuroscience Letters, 2003, 343, 81-84.	2.1	115
39	Efficient Recombinase-Mediated Cassette Exchange in hPSCs to Study the Hepatocyte Lineage Reveals AAVS1 Locus-Mediated Transgene Inhibition. Stem Cell Reports, 2015, 5, 918-931.	4.8	115
40	Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiology of Disease, 2004, 17, 21-28.	4.4	111
41	Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1G93A-induced motor neuron death. Neurobiology of Disease, 2007, 26, 332-341.	4.4	111
42	Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo. Human Molecular Genetics, 2017, 26, 2850-2863.	2.9	111
43	Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathologica, 2016, 132, 159-173.	7.7	109
44	Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nature Reviews Neuroscience, 2021, 22, 197-208.	10.2	107
45	GluR2 Deficiency Accelerates Motor Neuron Degeneration in a Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2005, 64, 605-612.	1.7	104
46	Axonal transport defects and neurodegeneration: Molecular mechanisms and therapeutic implications. Seminars in Cell and Developmental Biology, 2020, 99, 133-150.	5.0	102
47	Mibefradil (Ro 40m5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurones. Cell Calcium, 1997, 22, 299-311.	2.4	100
48	A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. Acta Neuropathologica, 2018, 135, 427-443.	7.7	98
49	Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiology of Disease, 2003, 13, 264-272.	4.4	97
50	Small Heat-Shock Protein HSPB1 Mutants Stabilize Microtubules in Charcot-Marie-Tooth Neuropathy. Journal of Neuroscience, 2011, 31, 15320-15328.	3.6	95
51	HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. Brain, 2018, 141, 673-687.	7.6	93
52	Defective axonal transport: A common pathological mechanism in inherited and acquired peripheral neuropathies. Neurobiology of Disease, 2017, 105, 300-320.	4.4	90
53	Upregulation of HSP27 in a Transgenic Model of ALS. Journal of Neuropathology and Experimental Neurology, 2002, 61, 968-974.	1.7	87
54	Mutant HSPB8 causes motor neuron-specific neurite degeneration. Human Molecular Genetics, 2010, 19, 3254-3265.	2.9	83

#	Article	IF	Citations
55	The G93C Mutation in Superoxide Dismutase 1. Archives of Neurology, 2006, 63, 262.	4.5	81
56	Human Wharton's Jelly-Derived Stem Cells Display a Distinct Immunomodulatory and Proregenerative Transcriptional Signature Compared to Bone Marrow-Derived Stem Cells. Stem Cells and Development, 2018, 27, 65-84.	2.1	81
57	Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain, 2016, 139, 1106-1122.	7.6	80
58	The neurobiology of amyotrophic lateral sclerosis. European Journal of Neuroscience, 2010, 31, 2247-2265.	2.6	78
59	VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiology of Aging, 2010, 31, 2185-2191.	3.1	78
60	Molecular Dissection of FUS Points at Synergistic Effect of Low-Complexity Domains in Toxicity. Cell Reports, 2018, 24, 529-537.e4.	6.4	74
61	Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcotâ€“Marieâ€“Tooth Disease. Neurotherapeutics, 2017, 14, 417-428.	4.4	67
62	Microglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1191-1200.	1.7	64
63	<scp>HDAC</scp>6 at the Intersection of Neuroprotection and Neurodegeneration. Traffic, 2012, 13, 771-779.	2.7	63
64	The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding. Neurobiology of Aging, 2013, 34, 2541-2547.	3.1	63
65	Restoration of Progranulin Expression Rescues Cortical Neuron Generation in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia. Stem Cell Reports, 2015, 4, 16-24.	4.8	62
66	The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 2014, 4, 223-239.	2.2	61
67	Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathologica Communications, 2019, 7, 107.	5.2	61
68	Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcotâ€“Marieâ€“Tooth Disease. ACS Chemical Neuroscience, 2016, 7, 240-258.	3.5	60
69	Rapamycin increases survival in ALS mice lacking mature lymphocytes. Molecular Neurodegeneration, 2013, 8, 31.	10.8	58
70	C9orf72 -derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Science Advances, 2021, 7, .	10.3	57
71	Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T)mice. Molecular Neurodegeneration, 2014, 9, 24.	10.8	56
72	Elongator subunit 3 (ELP3) modifies ALS through tRNA modification. Human Molecular Genetics, 2018, 27, 1276-1289.	2.9	56

#	Article	IF	Citations
73	G37R SOD1 mutant alters mitochondrial complex I activity, Ca2+ uptake and ATP production. Cell Calcium, 2011, 49, 217-225.	2.4	54
74	Vascular endothelial growth factor counteracts the loss of phosphoâ€Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2007, 33, 499-509.	3.2	53
75	Role of mitochondria in kainate-induced fast Ca2+ transients in cultured spinal motor neurons. Cell Calcium, 2007, 42, 59-69.	2.4	53
76	Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. Neurobiology of Disease, 2018, 111, 59-69.	4.4	52
77	HDAC6 inhibition restores TDPâ€43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO Journal, 2021, 40, e106177.	7.8	51
78	Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. ACS Chemical Neuroscience, 2019, 10, 1679-1695.	3.5	50
79	TDP-43 M311V mutation in familial amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 354-355.	1.9	49
80	Genetic Rodent Models of Amyotrophic Lateral Sclerosis. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-11.	3.0	49
81	Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS). Experimental Neurology, 2014, 262, 138-151.	4.1	48
82	Genetic variant in theHSPB1 promoter region impairs the HSP27 stress response. Human Mutation, 2007, 28, 830-830.	2.5	47
83	Astrocytes in amyotrophic lateral sclerosis: direct effects on motor neuron survival. Journal of Biological Physics, 2009, 35, 337-346.	1.5	47
84	Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells. Frontiers in Neuroscience, 2017, 11, 671.	2.8	47
85	C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transport. Scientific Reports, 2019, 9, 15728.	3.3	47
86	Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition. Stem Cell Reports, 2021, 16, 2213-2227.	4.8	47
87	ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Reports, 2022, 39, 110598.	6.4	47
88	Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 2007, 25, 8-16.	4.4	46
89	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
90	S100A6 Overexpression within Astrocytes Associated with Impaired Axons from Both ALS Mouse Model and Human Patients. Journal of Neuropathology and Experimental Neurology, 2002, 61, 736-744.	1.7	45

#	Article	IF	Citations
91	Testosterone boosts physical activity in male mice via dopaminergic pathways. Scientific Reports, 2018, 8, 957.	3.3	43
92	Overâ€expression of Hsp27 does not influence disease in the mutant SOD1^{G93A} mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2008, 106, 2170-2183.	3.9	42
93	The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS. European Journal of Neurology, 2010, 17, 754-756.	3.3	41
94	VEGF modulates NMDA receptors activity in cerebellar granule cells through Src-family kinases before synapse formation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13782-13787.	7.1	41
95	Differentiation but not ALS mutations in FUS rewires motor neuron metabolism. Nature Communications, 2019, 10, 4147.	12.8	41
96	Altered calcium dynamics and glutamate receptor properties in iPSC-derived motor neurons from ALS patients with C9orf72, FUS, SOD1 or TDP43 mutations. Human Molecular Genetics, 2019, 28, 2835-2850.	2.9	39
97	The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications. Brain, 2020, 143, 1651-1673.	7.6	39
98	A generic approach to study the kinetics of liquidâ€“liquid phase separation under near-native conditions. Communications Biology, 2021, 4, 77.	4.4	39
99	Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle and Nerve, 2006, 34, 391-405.	2.2	38
100	Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice. Molecular Neurodegeneration, 2018, 13, 55.	10.8	38
101	C9orf72 loss-of-function: a trivial, stand-alone or additive mechanism in C9 ALS/FTD?. Acta Neuropathologica, 2020, 140, 625-643.	7.7	38
102	Astrocyte-derived Jagged-1 mitigates deleterious Notch signaling in amyotrophic lateral sclerosis. Neurobiology of Disease, 2018, 119, 26-40.	4.4	35
103	Charcot-Marie-Tooth disease: Emerging mechanisms and therapies. International Journal of Biochemistry and Cell Biology, 2012, 44, 1299-1304.	2.8	33
104	FUS-induced neurotoxicity in Drosophila is prevented by downregulating nucleocytoplasmic transport proteins. Human Molecular Genetics, 2018, 27, 4103-4116.	2.9	33
105	Phasing in on the cell cycle. Cell Division, 2018, 13, 1.	2.4	33
106	ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Communications, 2020, 2, fcaa064.	3.3	33
107	Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 485-495.	1.7	32
108	Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis. NeuroReport, 2005, 16, 321-324.	1.2	29

#	Article	IF	Citations
109	Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors. Chemical Communications, 2015, 51, 9868-9871.	4.1	28
110	Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexaneâ€•or Cycloheptaneâ€Annulated 1,5â€Benzothiazepine Scaffold. Chemistry - A European Journal, 2017, 23, 128-136.	3.3	28
111	HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT. Brain Research, 2020, 1733, 146692.	2.2	28
112	HDAC6 as a potential therapeutic target for peripheral nerve disorders. Expert Opinion on Therapeutic Targets, 2018, 22, 993-1007.	3.4	27
113	Induced pluripotent stem cell-derived motor neurons of CMT type 2 patients reveal progressive mitochondrial dysfunction. Brain, 2021, 144, 2471-2485.	7.6	27
114	Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 11224.	4.1	27
115	Aire mediates thymic expression and tolerance of pancreatic antigens via an unconventional transcriptional mechanism. European Journal of Immunology, 2013, 43, 75-84.	2.9	26
116	Differential contribution of the Na ⁺ â€K ⁺ â€2Cl ^{â^'} cotransporter NKCC1 to chloride handling in rat embryonic dorsal root ganglion neurons and motor neurons. FASEB Journal, 2009, 23, 1168-1176.	0.5	24
117	Identification and characterization of Nanobodies targeting the EphA4 receptor. Journal of Biological Chemistry, 2017, 292, 11452-11465.	3.4	23
118	Role and therapeutic potential of liquidâ€“liquid phase separation in amyotrophic lateral sclerosis. Journal of Molecular Cell Biology, 2021, 13, 15-28.	3.3	23
119	PROSPECTIVE EXPLORATION OF BIOCHEMICAL TISSUE COMPOSITION VIA IMAGING MASS SPECTROMETRY GUIDED BY PRINCIPAL COMPONENT ANALYSIS. , 2006, , .		23
120	Arginine-rich Peptides Can Actively Mediate Liquid-liquid Phase Separation. Bio-protocol, 2017, 7, e2525.	0.4	23
121	Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 2537-2549.	2.8	21
122	Genetics of motor neuron disease. Current Neurology and Neuroscience Reports, 2006, 6, 423-431.	4.2	20
123	Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 2013, 7, 249.	3.7	20
124	Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis. British Journal of Pharmacology, 2021, 178, 1353-1372.	5.4	20
125	Loss of T cell microRNA provides systemic protection against autoimmune pathology in mice. Journal of Autoimmunity, 2012, 38, 39-48.	6.5	19
126	Genetic ablation of IP3receptor 2 increases cytokines and decreases survival ofSOD1G93Amice. Human Molecular Genetics, 2016, 25, 3491-3499.	2.9	19

#	Article	IF	Citations
127	Dantrolene is neuroprotective in vitro, but does not affect survival in SOD1G93A mice. Neuroscience, 2012, 220, 26-31.	2.3	18
128	Genetic ablation of phospholipase C delta 1 increases survival in SOD1G93A mice. Neurobiology of Disease, 2013, 60, 11-17.	4.4	18
129	Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis. IBRO Reports, 2019, 6, 74-86.	0.3	18
130	Liquidâ€“Liquid Phase Separation Enhances TDP-43 LCD Aggregation but Delays Seeded Aggregation. Biomolecules, 2021, 11, 548.	4.0	18
131	EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 102.	6.2	17
132	Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcotâ€“Marieâ€“Tooth Type 2A Mouse Model. Journal of Medicinal Chemistry, 2021, 64, 4810-4840.	6.4	17
133	Microglia in amyotrophic lateral sclerosis. Acta Neurologica Belgica, 2007, 107, 63-70.	1.1	17
134	Sequence and Spatial Requirements for Regulated Muscle-specific Processing of the Sarco/Endoplasmic Reticulum Ca2+-ATPase 2 Gene Transcript. Journal of Biological Chemistry, 1995, 270, 11004-11011.	3.4	16
135	Calcium handling proteins in isolated spinal motoneurons. Life Sciences, 1999, 65, 1597-1606.	4.3	16
136	Conditional deletion of Id2 or Notch1 in oligodendrocyte progenitor cells does not ameliorate disease outcome in SOD1G93A mice. Neurobiology of Aging, 2018, 68, 1-4.	3.1	16
137	A shortened tamoxifen induction scheme to induce CreER recombinase without side effects on the male mouse skeleton. Molecular and Cellular Endocrinology, 2017, 452, 57-63.	3.2	15
138	In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 129, 79-92.	4.4	15
139	The Role of Nucleocytoplasmic Transport Defects in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 12175.	4.1	14
140	Regulation of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 2 gene transcript in neuronal cells. Molecular Brain Research, 1998, 55, 92-100.	2.3	13
141	Sequence elements surrounding the acceptor site suppress alternative splicing of the sarco/endoplasmic reticulum Ca2+-ATPase 2 gene transcript. Biochemical Journal, 1997, 322, 885-891.	3.7	12
142	Neuronal overexpression of IP3 receptor 2 is detrimental in mutant SOD1 mice. Biochemical and Biophysical Research Communications, 2012, 429, 210-213.	2.1	12
143	Integrated molecular landscape of amyotrophic lateral sclerosis provides insights into disease etiology. Brain Pathology, 2018, 28, 203-211.	4.1	12
144	In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration. Journal of Visualized Experiments, 2018, , .	0.3	12

#	Article	IF	Citations
145	AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS. Molecular Therapy - Methods and Clinical Development, 2021, 20, 508-519.	4.1	12
146	Lighting Up the Plasma Membrane: Development and Applications of Fluorescent Ligands for Transmembrane Proteins. Chemistry - A European Journal, 2021, 27, 8605-8641.	3.3	12
147	Progranulin does not affect motor neuron degeneration in mutant SOD1 mice and rats. Neurobiology of Aging, 2013, 34, 2302-2303.	3.1	11
148	Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2019, 7, 114.	5.2	11
149	Potential Therapeutic Role of HDAC Inhibitors in FUS-ALS. Frontiers in Molecular Neuroscience, 2021, 14, 686995.	2.9	11
150	Modulation of SERCA2 activity: Regulated splicing and interaction with phospholamban. Bioscience Reports, 1995, 15, 307-315.	2.4	10
151	Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis. Scientific Reports, 2019, 9, 14112.	3.3	10
152	RT2 PCR array screening reveals distinct perturbations in DNA damage response signaling in FUS-associated motor neuron disease. Molecular Brain, 2019, 12, 103.	2.6	10
153	CMT2Q-causing mutation in the Dhtkd1 gene lead to sensory defects, mitochondrial accumulation and altered metabolism in a knock-in mouse model. Acta Neuropathologica Communications, 2020, 8, 32.	5.2	10
154	Impact of prolonged sepsis on neural and muscular components of muscle contractions in a mouse model. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 443-455.	7.3	10
155	Alternative processing of the sarco/endoplasmic reticulum Ca2+-ATPase transcripts during muscle differentiation is a specifically regulated process. Biochemical Journal, 1996, 317, 647-651.	3.7	9
156	Existing and Emerging Metabolomic Tools for ALS Research. Genes, 2019, 10, 1011.	2.4	9
157	Tissue-type plasminogen activator is not required for kainate-induced motoneuron death in vitro. NeuroReport, 1998, 9, 2791-2796.	1.2	8
158	Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 418-420.	3.1	8
159	HDAC6 and Miro1: Another interaction causing trouble in neurons. Journal of Cell Biology, 2019, 218, 1769-1770.	5.2	8
160	Exploring the alternative: Fish, flies and worms as preclinical models for ALS. Neuroscience Letters, 2021, 759, 136041.	2.1	8
161	Therapeutic potential of HDAC6 in amyotrophic lateral sclerosis. Cell Stress, 2018, 2, 14-16.	3.2	8
162	Different pattern of differentiation in two LLC-PK1 Clones. Journal of Cellular Physiology, 1989, 141, 483-489.	4.1	7

#	Article	IF	Citations
163	Long-lasting changes in GABA responsiveness in cultured neurons. Neuroscience Letters, 2004, 365, 69-72.	2.1	7
164	L-Î²-N-oxalyl-Î±,Î²-diaminopropionic acid toxicity in motor neurons. NeuroReport, 2011, 22, 131-135.	1.2	7
165	The role of histone deacetylase 6 (HDAC6) in neurodegeneration. Research and Reports in Biology, 0, , 1.	0.2	7
166	HDAC3 Inhibition Stimulates Myelination in a CMT1A Mouse Model. Molecular Neurobiology, 2022, 59, 3414-3430.	4.0	7
167	F/YGG-motif is an intrinsically disordered nucleic-acid binding motif. RNA Biology, 2022, 19, 622-635.	3.1	7
168	The pathogenesis of amyotrophic lateral sclerosis. Neuroscience Research Communications, 1998, 23, 67-75.	0.2	5
169	NKCC1 downregulation induces hyperpolarizing shift of GABA responsiveness at near term fetal stages in rat cultured dorsal root ganglion neurons. BMC Neuroscience, 2015, 16, 41.	1.9	5
170	Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology. Biomolecules, 2022, 12, 440.	4.0	5
171	Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress Granules. Biomedicines, 2022, 10, 1057.	3.2	5
172	C-kit is important for SOD1G93A mouse survival independent of mast cells. Neuroscience, 2015, 301, 415-420.	2.3	4
173	Reply to â€˜TDP43 aggregates: the â€˜SchrÃ¶dingerâ€™s catâ€™ in amyotrophic lateral sclerosisâ€™. Nature Reviews Neuroscience, 2021, 22, 515-515.	10.2	4
174	Generation of Human Motor Units with Functional Neuromuscular Junctions in Microfluidic Devices. Journal of Visualized Experiments, 2021, , .	0.3	4
175	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
176	Regulation of Alternative Splicing of the SERCA2 Pre-mRNA in Muscle. Annals of the New York Academy of Sciences, 1998, 853, 372-375.	3.8	3
177	Synaptopodin and 4 novel genes identified in primary sensory neurons. Molecular and Cellular Neurosciences, 2005, 30, 316-325.	2.2	3
178	Transcriptional upregulation of myelin components in spontaneous myelin basic protein-deficient mice. Brain Research, 2015, 1606, 125-132.	2.2	3
179	Targeting Axonal Transport: A New Therapeutic Avenue for ALS. , 2020, , .		3
180	Lowering EphA4 Does Not Ameliorate Disease in a Mouse Model for Severe Spinal Muscular Atrophy. Frontiers in Neuroscience, 2019, 13, 1233.	2.8	2

#	Article	IF	Citations
181	Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of Neurodegeneration. Bio-protocol, 2020, 10, e3659.	0.4	2
182	Isoform Diversity and Regulation of Organellar-Type Ca2+-Transport ATPases. Advances in Molecular and Cell Biology, 1997, 23, 205-248.	0.1	1
183	Chapter 10 Excitotoxicity and Oxidative Stress in Pathogenesis of Amyotrophic Lateral Sclerosis/Motor Neuron Disease. Blue Books of Practical Neurology, 2003, 28, 259-cp1.	0.1	1
184	Chapter 19 Therapies in amyotrophic lateral sclerosis: Options for the near and far future. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 82, 375-387.	1.8	1
185	Amyotrophic lateral sclerosis: mechanisms and therapeutic strategies. , 2017, , 277-296.		1
186	Animal Models of Amyotrophic Lateral Sclerosis. Neuromethods, 2011, , 515-531.	0.3	1
187	The Astrocytic Contribution in ALS: Inflammation and Excitotoxicity. , 0, , .		0
188	Endoplasmic reticulum stress plays an important role in amyotrophic lateral sclerosis (Commentary) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.6	0
189	Frontispiece: Lighting Up the Plasma Membrane: Development and Applications of Fluorescent Ligands for Transmembrane Proteins. Chemistry - A European Journal, 2021, 27, .	3.3	0